Domača stranNVO • NYSE
add
Novo Nordisk
37,45 $
Po zaprtju:(0,11 %)+0,039
37,49 $
Konec trgovanja: 27. feb., 19:59:15 GMT -5 · USD · NYSE · Izjava
Prejšnji trg. dan.
37,62 $
Dnevni razpon
37,33 $ - 37,86 $
Letni razpon
37,31 $ - 91,90 $
Tržna kapitalizacija
127,30 mrd. USD
Povprečni obseg
28,42 mio.
Razm. P/E
10,30
Dividendna donosnost
4,97 %
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (DKK) | dec. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 79,14 mrd. | −7,63 % |
Stroški poslovanja | 29,73 mrd. | 12,96 % |
Čisti dohodek | 26,89 mrd. | −4,74 % |
Čista dobičkovnost prihodkov | 33,98 | 3,13 % |
Earnings per share | 6,04 | −4,73 % |
EBITDA | 36,66 mrd. | −23,44 % |
Efektivna davčna stopnja | 21,34 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (DKK) | dec. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 26,96 mrd. | 2,49 % |
Skupna sredstva | 542,90 mrd. | 16,60 % |
Skupne obveznosti | 348,86 mrd. | 8,29 % |
Celoten lastniški kapital | 194,05 mrd. | — |
Shares outstanding | 4,44 mrd. | — |
Razmerje P/B | 0,86 | — |
Donosnost sredstev | 16,70 % | — |
Donosnost kapitala | 29,56 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (DKK) | dec. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 26,89 mrd. | −4,74 % |
Denar iz dejavnosti | 7,62 mrd. | −38,06 % |
Denar iz naložb | −42,81 mrd. | 53,07 % |
Denar iz financiranja | 29,47 mrd. | −20,00 % |
Neto sprememba denarnih sredstev | −5,62 mrd. | 86,41 % |
Prost denarni tok | −34,95 mrd. | −1.011,09 % |
Vizitka
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Generalni direktor
Datum ustanovitve
21. dec. 1923
Sedež organizacije
Spletno mesto
Zaposleni
69.150
